<DOC>
	<DOCNO>NCT01114139</DOCNO>
	<brief_summary>To evaluate efficacy safety IV ferumoxytol compare placebo treatment iron deficiency anemia ( IDA ) .</brief_summary>
	<brief_title>A Trial Ferumoxytol Treatment Iron Deficiency Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>Key Inclusion Criteria include : 1 . Males females ≥18 year age 2 . Subjects IDA 3 . Subjects history unsatisfactory oral iron therapy oral iron use 4 . Female subject childbearing potential sexually active must effective method birth control least 1 month prior screen agree remain birth control completion participation study Key Exclusion Criteria include : 1 . History allergy IV iron 2 . Allergy two class drug 3 . Subjects dialysis estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73m2 4 . Female subject pregnant , intend become pregnant , breastfeeding , within 2 week postpartum , positive serum/urine pregnancy test 5 . Hemoglobin ≤7.0 g/dL 6 . Serum ferritin &gt; 600 ng/mL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Iron deficiency anemia</keyword>
	<keyword>Feraheme</keyword>
	<keyword>ferumoxytol</keyword>
	<keyword>AUB</keyword>
	<keyword>cancer</keyword>
	<keyword>GI disorder</keyword>
	<keyword>postpartum anemia</keyword>
	<keyword>The treatment iron deficiency anemia ( IDA )</keyword>
</DOC>